Diclofenac etalhyaluronate - Seikagaku Corporation

Drug Profile

Diclofenac etalhyaluronate - Seikagaku Corporation

Alternative Names: Hyaluronic acid/non-steroidal anti-inflammatory drug; Hyaluronic acid/NSAID; ONO 5704; SI-613

Latest Information Update: 09 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Seikagaku Corporation
  • Developer Ono Pharmaceutical; Seikagaku Corporation
  • Class Amides; Antirheumatics; Drug conjugates; Glycosaminoglycans; Nonsteroidal anti-inflammatories
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Osteoarthritis
  • Phase II Tendinitis

Most Recent Events

  • 01 Feb 2018 Seikagaku Corporation and Ono Pharmaceutical initiate enrolment in a long-term follow-up phase III trial for Osteoarthritis in Japan (Intra-articular) (JapicCTI-183855)
  • 28 Sep 2017 Phase-II clinical trials in Tendinitis in Japan (unspecified route)
  • 01 Sep 2017 Seikagaku Corporation and Ono Pharmaceutical reach a definitive agreement to co-promote and co-develop SI 613 for Osteoarthritis in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top